BridgeBio Encaleret NDA: $16B for a 5,000-Patient Market

BridgeBio Pharma (BBIO) closed at $82.93 on July 23 with a $16.2 billion market cap. The FDA accepted its NDA for encaleret on July 22, assigning a PDUFA date of May 8, 2027. If approved, encaleret becomes the first and only therapy specifically indicated for autosomal dominant hypocalcemia type 1 (ADH1). The CALIBRATE Phase 3 data is excellent. The valuation is the question.

ADH1 is a disease most doctors have never heard of. BridgeBio is betting $16 billion that they will start hearing about it.

The disease: a broken calcium thermostat

ADH1 is a rare genetic disorder caused by gain-of-function variants in the calcium-sensing receptor gene (CASR). The CASR acts as the body’s calcium thermostat. It tells the kidneys how much calcium to keep and how much to excrete, and it tells the parathyroid glands how much parathyroid hormone (PTH) to produce. In ADH1, that thermostat is set too high. The kidneys leak calcium into the urine even when blood calcium is dangerously low. The parathyroid glands shut down PTH production because the broken receptor tells them blood calcium is fine when it is not.

The result: patients cycle through symptoms for years. Muscle cramps, seizures, laryngospasm, brain fog. The literature review published in PMC identified 338 published cases across 113 distinct CASR variants. The median age at diagnosis of a hypocalcemia-related disorder was 4 years. But the median age at complete genetic diagnosis of ADH1 specifically was 25 years. That 21-year gap is the diagnostic odyssey these patients endure. Most are initially misdiagnosed with idiopathic hypoparathyroidism (93% of cases in the literature review).

The standard of care makes the disease worse. Calcium and vitamin D supplements raise blood calcium but do not stop the kidneys from leaking calcium. Patients on standard care develop hypercalciuria (excessive urinary calcium), which leads to kidney stones and nephrocalcinosis, progressive kidney damage from calcium deposits. The treatment causes the complication. This is the unmet need that encaleret addresses.

The prevalence estimate matters for the business case. ADH1 prevalence ranges from 1 in 70,000 to 3.9 per 100,000 in the literature. At the midpoint, that suggests roughly 3,000 to 5,000 US patients. BridgeBio has argued, based on human genetics evidence, that the true prevalence may be higher due to underdiagnosis. That claim is plausible given the diagnostic gap, but it is unproven.

The CALIBRATE data: clean and compelling

The Phase 3 CALIBRATE trial (NCT05680818) enrolled 67 patients aged 16 to 76 with ADH1 due to 46 distinct CASR variants. The design was open-label, randomized, controlled. Patients were their own controls: they spent a period on standard of care, then switched to encaleret.

The composite primary endpoint measured the proportion of encaleret-treated patients achieving both target albumin-corrected blood calcium (8.3-10.7 mg/dL) and target 24-hour urinary calcium (below 300 mg/day for males, below 250 mg/day for females) at Week 24, compared to the same patients on standard of care.

The results, presented at ENDO 2026:

• Primary endpoint met: 75.6% of encaleret-treated patients achieved both blood and urine calcium targets at Week 24, compared to only 4.4% on standard of care (p<0.0001).
• PTH restoration: 91.1% of encaleret patients achieved PTH of 15 pg/mL or higher (normal range 15-65) at Week 24, compared to 6.7% on standard of care (p<0.0001). In the standard of care group, 0% achieved normal PTH.
• Serum phosphate normalization: 91.1% of encaleret patients vs 55.6% on standard of care (p=0.0003).
• Speed of response: Blood calcium improved by Day 3 of treatment. Urinary calcium decreased by Week 3. Improvements were maintained through Week 24.

This is a drug that fixes the root cause. Encaleret is a calcium-sensing receptor negative modulator. It quiets the overactive CASR, allowing the kidneys to retain calcium and the parathyroid glands to resume normal PTH production. The 75.6% responder rate in a disease where the standard of care manages symptoms is a genuine therapeutic advance.

The FDA told BridgeBio it is not currently planning to hold an advisory committee meeting. That matters. When the FDA skips an AdComm, it signals the agency does not see controversial issues worth a panel discussion. The data is clean enough that the regulators do not need outside experts to weigh in. This de-risks the approval path significantly. For contrast, see our analysis of Madrigal’s resmetirom in MASH, where the FDA scheduled an AdComm to scrutinize cardiac safety signals. Encaleret has no comparable safety controversy.

The competitive picture: Takeda’s exit is BridgeBio’s opening

The hypoparathyroidism market has one approved product: Ascendis Pharma’s Yorvipath (palopegteriparatide), approved in October 2025. Yorvipath is a PTH prodrug, a daily subcutaneous injection that replaces the missing hormone. It works for the broader hypoparathyroidism population, which includes both surgical and genetic causes.

But here is the key: Yorvipath treats symptoms, not the underlying mechanism. It replaces PTH but does not fix the broken calcium-sensing receptor. And in ADH1 specifically, PTH replacement can be dangerous because the kidneys still leak calcium. Encaleret is the first drug that addresses the root cause of ADH1.

Takeda’s exit from the market is the back story. Takeda discontinued all manufacturing of Natpara (parathyroid hormone) by the end of 2024, citing manufacturing challenges. Natpara was the only PTH replacement option for years, and its withdrawal left the hypoparathyroidism market without a single approved treatment until Yorvipath launched. Ascendis Pharma (ASND) now trades at $16.6 billion market cap with Yorvipath as its lead commercial asset.

The competitive dynamics are straightforward. Encaleret would not compete with Yorvipath for the broader hypoparathyroidism market. It targets ADH1 specifically, a genetic subtype. But BridgeBio is also planning RECLAIM-HP, a Phase 3 trial in chronic hypoparathyroidism more broadly. If encaleret expands beyond ADH1, it competes directly with Yorvipath. That is the multi-billion-dollar opportunity the bull case depends on.

The valuation: pricing in a $1 billion-plus pipeline

At $82.93 per share with 195.9 million shares outstanding (per Polygon), BridgeBio’s market cap is $16.24 billion. That is a staggering number for a company whose only commercial product, Attruby (acoramidis) for ATTR cardiomyopathy, generated $180.6 million in US net product revenue in Q1 2026. The full-year 2025 revenue was $502.1 million.

BridgeBio is not a one-drug company. It has Attruby ramping (up from $1.7 million in 2023 to $502 million in 2025), encaleret approaching approval, and a broader pipeline including BBP-418 for LGMD2i (PDUFA November 27, 2026) and a pan-KRAS program. But the $16 billion market cap prices in significant success across multiple programs.

Compare to Ascendis Pharma at $16.6 billion. Ascendis has Yorvipath already on the market with orphan drug exclusivity. BridgeBio has Attruby ramping and encaleret a year out. The two companies trade at nearly identical market caps, but Ascendis has a commercial product in the endocrine space already. BridgeBio is valued on future potential.

Compare to BioMarin (BMRN) at $11.4 billion. BioMarin has a portfolio of approved rare disease drugs generating $2.8 billion in annual revenue. BridgeBio has $502 million in annual revenue and trades at a 42% premium to BioMarin. That premium requires encaleret and the pipeline to deliver revenue above $1 billion, the peak sales figure BridgeBio management itself has cited for the ADH1 opportunity. The same premium-vs-revenue gap exists in oncology, as we noted in our Moderna mRNA cancer vaccine analysis, where platform optionality commands a valuation premium over current sales. For more on how rare disease valuations work, see our GSK Jideytro approval analysis, which covers the premium pharma pays for rare disease assets.

The risk: underdiagnosis is the whole ballgame

The ADH1 market is small. At 3,000 to 5,000 US patients, even at $100,000 per year (roughly in line with Yorvipath’s expected pricing), the US revenue ceiling is $300 to $500 million. That does not justify the $16 billion valuation. The bull case requires either higher prevalence than the literature suggests, label expansion into chronic hypoparathyroidism via RECLAIM-HP, or significant international revenue from the planned EMA submission in H2 2026.

The specific risk: underdiagnosis is a two-edged sword. BridgeBio argues the true prevalence is higher than published estimates because most patients are misdiagnosed. That may be true, but it means the company has to invest in physician education and genetic testing infrastructure to find the patients. That is expensive and slow. Rare disease drug launches can take 3 to 5 years to reach peak penetration. The CALIBRATE-PEDS pediatric trial is still enrolling, meaning the pediatric label expansion is further out.

The next catalyst is the EMA MAA submission in H2 2026. Europe represents roughly half the rare disease market, but the pricing environment is tougher than the US.

The verdict

The CALIBRATE data is clean, the “no adcomm” signal is positive, and encaleret is the first drug to fix the root cause of ADH1. The science is real. But at $16.2 billion, BridgeBio is priced for encaleret to succeed and for the pipeline to deliver. A $300 to $500 million US ADH1 opportunity does not move the needle on a $16 billion valuation. The stock needs RECLAIM-HP to expand the label and international revenue to justify current levels.

I would not short BBIO. The Attruby ramp and the pipeline optionality are real. But I would not add at $83. The risk-reward favors waiting for a pullback to the $70-75 range or for the EMA submission to de-risk the international story. The May 2027 PDUFA is 10 months out. That is a long time for a $16 billion company to stay on a single positive catalyst. The number to watch is Attruby quarterly revenue growth. If it continues to ramp, the encaleret optionality is free. If it stalls, the stock has too much priced in.

Source: CALIBRATE trial, ClinicalTrials.gov NCT05680818 | BridgeBio NDA acceptance press release